. 2012 Dec 6;14(12):764–770. doi: 10.5812/ircmj.1302

Table 3. Comparison of Some Related Published Articles.

Reference	Year	Country	Site	Subtype	Number	Method	Result (% positive for EBV)
Ko et al. (31)	2004	Korea	ENNHL ^a	TCL ^a	11	ISH- EBER ^a	54%
Ko et al. (31)	2004	Korea	ENNHL ^a	TCL ^a	11	PCR	0%
Mitarnun et al. (24)	2006	Thailand	Sino nasal	89%TCL	16	ISH - EBER	100%
			Sino nasal	11%BCL	2		0%
			Nasopharynx	17%TCL	7		100%
			Nasopharynx	83%BCL	35		5.4%
Feng et al. (33)	2007	China	Sino nasal	DLBL ^a	6	PCR and ISH For all cases	0%
Feng et al. (33)	2007	China	Sino nasal	NKC ^a /T cell	44	PCR and ISH For all cases	100%
Tai et al. (6)	2004	Thailand	Sino nasal	NKC/T cell	20	PCR	100%
Quintanilla-Martinez et al. (25)	1999	Peru	Sino nasal	NKC/T cell	28	ISH-EBER	90%
van de Rijn et al. (23)	1997	Guatemala	Sino nasal	Head and neck	17	ISH-EBER	38%
Bahnassy et al (35)	2006	Egypt	EN-NHL head and neck	62% B-cell	50	PCR	70%
				18% T-cell		ISH-EBER	90%
				20% Nk-cell		ISH-EBER	90%
Ko et al. (31)	1994	Korea	NHL	TCL	50	ISH-EBER	61%
Ko et al. (31)	1994	Korea	NHL	BCL ^a	50	ISH-EBER	24%
Calzolari et al. (19)	1998	Italy	Oral NHL (HIV Patients)	DLBL	6	ISH-EBER	100%
Leong et al. (21)	2001	Canada	Oral NHL	All subtypes	9 Immuno compramised	ISH-EBER	100%
					9 Immuno compramised	IHC-LMP	62%
					46 Immuno competent	ISH-EBER	34%
					46 Immuno competent	IHC-LMP	10%
				DLBL	22 Immuno compramis	ISH-EBER	27%
					22 Immuno compramis	IHC-LMP	9%
					3 Immuno competent	ISH-EBER	100%
					3 Immuno competent	IHC-LMP	100%
Mitarnun et al. (24)	2006	Thailand	NHL	BCL	100	ISH-EBER	13%
				TCL	100	ISH-EBER	51%
				CHL	100	ISH-EBER	64%
Takahara et al. (32)	2004	Japan	NHL	NK/TCL	32	ISH-EBER	96%
Takahara et al. (32)	2004	Japan	NHL	NK/TCL	32	PCR	48%

^aAbbreviations: TCL: T- cell lymphoma, BCL: B cell lymphoma, NKC: Natural killer cell, EN-NHL: Extra Nodal Non-Hodgkin’s lymphoma, DLBL: Diffuse large B cell lymphoma, ISH-EBER: In Situ Hybridization -EBV (Epstein-Bar Virus)-Encoded RNA (Ribonucleic Acid)